Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection

In the final results of a randomized trial involving patients with HIV infection, pitavastatin reduced the incidence of adverse cardiovascular events at 5.6 years of follow-up as compared with placebo.